Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus R2-GemOx in R/R DLBCL
NCT05186558Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Planned start May 2022; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05186558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186558.